TY  - JOUR
A1  - Fahrleitner-Pammer, Astrid
A1  - Papaioannou, Nikolaos
A1  - Gielen, Evelien
A1  - Feudjo Tepie, Maurille
A1  - Toffis, Chris
A1  - Frieling, Isolde
A1  - Geusens, Piet
A1  - Makras, Polyzois
A1  - Boschitsch, Ewald
A1  - Callens, Joris
A1  - Anastasilakis, Athanasios D.
A1  - Niedhart, Christopher
A1  - Resch, Heinrich
A1  - Kalouche-Khalil, Lama
A1  - Hadji, Peyman
T1  - Factors associated with high 24-month persistence with denosumab : results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium
T2  - Archives of osteoporosis
N2  - Summary: Persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium found that persistence with denosumab remains consistently high after 24 months in patients at high risk of fracture.
Purpose: Continued persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of clinical practice evaluated medication-taking behavior of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium and factors influencing persistence.
Methods: Subcutaneous denosumab (60 mg every 6 months) was assigned according to prescribing information and local guidelines before and independently of enrollment; outcomes were recorded during routine practice for up to 24 months. Persistence was defined as receiving the subsequent injection within 6 months + 8 weeks of the previous injection and adherence as administration of subsequent injections within 6 months ± 4 weeks of the previous injection. Medication coverage ratio (MCR) was calculated as the proportion of time a patient was covered by denosumab. Associations between pre-specified baseline covariates and 24-month persistence were assessed using multivariable logistic regression.
Results: The 24-month analyses included 1479 women (mean age 66.3–72.5 years) from 140 sites; persistence with denosumab was 75.1–86.0%, adherence 62.9–70.1%, and mean MCR 87.4–92.4%. No covariate had a significant effect on persistence across all four countries. For three countries, a recent fall decreased persistence; patients were generally older with chronic medical conditions. In some countries, other covariates (e.g., older age, comorbidity, immobility, and prescribing reasons) decreased persistence. Adverse drug reactions were reported in 2.3–6.9% patients.
Conclusions: Twenty-four-month persistence with denosumab is consistently high among postmenopausal women in Europe and may be influenced by patient characteristics. Further studies are needed to identify determinants of low persistence.
KW  - Adherence
KW  - Compliance
KW  - Denosumab
KW  - Non-interventional study
KW  - Osteoporosis
KW  - Persistence
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45652
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-456524
SN  - 1862-3514
SN  - 1862-3522
N1  - © The Author(s) 2017. Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
VL  - 12
IS  - 1, Art. 58
SP  - 1
EP  - 13
PB  - Springer
CY  - London [u. a.]
ER  -